|
|
News Breaks | | | | January 7, 2013 | | 07:04 EDT |  | AUXL | Auxilium expands exclusive license of Xiaflex to include cellulite treatment
Auxilium announced that it has exercised its exclusive option under the Second Amended and Restated Development and License Agreement with BioSpecifics Technologies to expand the field of its license for collagenase clostridium histolyticum to include the potential treatment of adult patients with edematous fibrosclerotic panniculopathy, commonly known as cellulite. The company exercised its option to include cellulite as an additional indication by making a one-time license fee payment of $500,000 to BioSpecifics. As a result of this exercise, the company's exclusive, world-wide license has now been expanded, subject to the terms of the CCH License Agreement, to include all research, development, use, commercialization, marketing, sales and distribution rights for CCH for the potential treatment of cellulite. | |
|
News For AUXL From The Last 14 Days Check below for free stories on AUXL the last two weeks. |
|
|
| June 14, 2013 | | 10:10 EDT |  | AUXL | On The Fly: Analyst Initiation Summary
 Subscribe for More Information | | | June 13, 2013 | | 16:06 EDT | | AUXL | Auxilium initiated with a Buy at Mizuho
Target $28. | |
|
|
|
|
|
|
